بدائل البحث:
ppm decrease » _ decrease (توسيع البحث), nn decrease (توسيع البحث), pa decreased (توسيع البحث)
ng decrease » nn decrease (توسيع البحث), _ decrease (توسيع البحث), we decrease (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
50 ppm » 5 ppm (توسيع البحث)
50 ng » 50 mg (توسيع البحث), 5 ng (توسيع البحث), 50 ns (توسيع البحث)
10 ng » 100 ng (توسيع البحث), 10 mg (توسيع البحث), 10 nm (توسيع البحث)
50 a » 50 μ (توسيع البحث), 50 _ (توسيع البحث), 50 c (توسيع البحث)
ppm decrease » _ decrease (توسيع البحث), nn decrease (توسيع البحث), pa decreased (توسيع البحث)
ng decrease » nn decrease (توسيع البحث), _ decrease (توسيع البحث), we decrease (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
50 ppm » 5 ppm (توسيع البحث)
50 ng » 50 mg (توسيع البحث), 5 ng (توسيع البحث), 50 ns (توسيع البحث)
10 ng » 100 ng (توسيع البحث), 10 mg (توسيع البحث), 10 nm (توسيع البحث)
50 a » 50 μ (توسيع البحث), 50 _ (توسيع البحث), 50 c (توسيع البحث)
-
81
-
82
-
83
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
منشور في 2022"…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …"
-
84
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
منشور في 2022"…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …"
-
85
-
86
Description of the cohort (N = 118 patients).
منشور في 2023"…An HLA-G plasma level ≤ 50 ng/ml on day 8 after LT was significantly associated with a higher rejection risk. …"
-
87
-
88
-
89
-
90
-
91
Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50.
منشور في 2024"…Relative band densities from three independent experiments were analyzed. (A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …"
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
Effect of 10 ng of IL-1β and IL-1Ra in a preliminary recording of the LFPs in the OB.
منشور في 2025"…<p>A) A single dose of 10 ng of IL-1β decreased the amplitude of LFPs in the OB immediately after its microinjection, reaching a maximum effect at approximately 10 min and remaining constant for at least 45 min. …"